SLNO FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Stock analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Soleno Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($2.85) per share for the year, down from their previous forecast of ($2.65). Cantor Fitzgerald has a “Overweight” rating and a $123.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

SLNO has been the topic of several other research reports. Guggenheim reaffirmed a “buy” rating and set a $81.00 target price (up previously from $70.00) on shares of Soleno Therapeutics in a research report on Friday. Stifel Nicolaus raised their price target on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a report on Friday. Laidlaw upped their price target on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. HC Wainwright lifted their target price on shares of Soleno Therapeutics from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Robert W. Baird boosted their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $98.86.

Soleno Therapeutics Stock Performance

NASDAQ SLNO opened at $71.45 on Monday. The company’s 50-day simple moving average is $49.44 and its two-hundred day simple moving average is $50.23. Soleno Therapeutics has a one year low of $36.61 and a one year high of $73.97. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of -21.52 and a beta of -1.70.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

Insider Transactions at Soleno Therapeutics

In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total transaction of $496,649.17. Following the completion of the transaction, the chief executive officer now owns 708,616 shares of the company’s stock, valued at $32,178,252.56. This represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael F. Huang sold 14,583 shares of the business’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $69.51, for a total value of $1,013,664.33. Following the sale, the vice president now owns 36,817 shares of the company’s stock, valued at $2,559,149.67. The trade was a 28.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 956,250 shares of company stock valued at $64,583,745 in the last ninety days. 12.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Soleno Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. AlphaQuest LLC lifted its position in Soleno Therapeutics by 1,154.4% during the fourth quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after buying an additional 658 shares in the last quarter. US Bancorp DE purchased a new stake in shares of Soleno Therapeutics in the 4th quarter valued at approximately $34,000. Avanza Fonder AB acquired a new position in Soleno Therapeutics in the fourth quarter valued at approximately $76,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in Soleno Therapeutics during the fourth quarter worth $81,000. Finally, Avior Wealth Management LLC acquired a new position in shares of Soleno Therapeutics in the 4th quarter valued at $89,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.